![Page 1: Electronic Transfer of Serious Adverse Events to Global Pharmacovigilance PhUSE, Berlin, October 2010 Eva Bervar Bayer Vital GmbH, Leverkusen](https://reader036.vdocument.in/reader036/viewer/2022062718/56649e6a5503460f94b67a38/html5/thumbnails/1.jpg)
Electronic Transfer ofSerious Adverse Events to Global Pharmacovigilance
PhUSE, Berlin, October 2010
Eva BervarBayer Vital GmbH, Leverkusen
![Page 2: Electronic Transfer of Serious Adverse Events to Global Pharmacovigilance PhUSE, Berlin, October 2010 Eva Bervar Bayer Vital GmbH, Leverkusen](https://reader036.vdocument.in/reader036/viewer/2022062718/56649e6a5503460f94b67a38/html5/thumbnails/2.jpg)
GCOData
Management
2
Agenda
• Introduction
• Paper-Based SAE Reporting
• Electronic SAE Reporting
• Implementation
![Page 3: Electronic Transfer of Serious Adverse Events to Global Pharmacovigilance PhUSE, Berlin, October 2010 Eva Bervar Bayer Vital GmbH, Leverkusen](https://reader036.vdocument.in/reader036/viewer/2022062718/56649e6a5503460f94b67a38/html5/thumbnails/3.jpg)
GCOData
Management
3
Introduction
• Reconciliation of Serious Adverse Events (SAE) is done between
- Clinical Database (GDM) and
- Global Pharmacovigilance Database (PV)
• Regular SAEs reporting via fax to PV (manual process)
• SAS macro used to compare GDM and PV databases
- Creation of three different integrated reports
• Implementation of electronic process currently in pilot phase
![Page 4: Electronic Transfer of Serious Adverse Events to Global Pharmacovigilance PhUSE, Berlin, October 2010 Eva Bervar Bayer Vital GmbH, Leverkusen](https://reader036.vdocument.in/reader036/viewer/2022062718/56649e6a5503460f94b67a38/html5/thumbnails/4.jpg)
GCOData
Management
4
Matching of Subjects/SAEs
![Page 5: Electronic Transfer of Serious Adverse Events to Global Pharmacovigilance PhUSE, Berlin, October 2010 Eva Bervar Bayer Vital GmbH, Leverkusen](https://reader036.vdocument.in/reader036/viewer/2022062718/56649e6a5503460f94b67a38/html5/thumbnails/5.jpg)
GCOData
Management
5
SAE Report-Subject Match
• Subject Match
![Page 6: Electronic Transfer of Serious Adverse Events to Global Pharmacovigilance PhUSE, Berlin, October 2010 Eva Bervar Bayer Vital GmbH, Leverkusen](https://reader036.vdocument.in/reader036/viewer/2022062718/56649e6a5503460f94b67a38/html5/thumbnails/6.jpg)
GCOData
Management
6
SAE Reports-SAE Match
• SAE match
match
non match
• Other important item comparison
}
}
![Page 7: Electronic Transfer of Serious Adverse Events to Global Pharmacovigilance PhUSE, Berlin, October 2010 Eva Bervar Bayer Vital GmbH, Leverkusen](https://reader036.vdocument.in/reader036/viewer/2022062718/56649e6a5503460f94b67a38/html5/thumbnails/7.jpg)
GCOData
Management
7
Limitations of Current Process
• Manual process via fax and data entry into PV database needed
• More discrepancies, because of two sources for SAE information (Complementary page and EDC CRF)
• Reconciliation between PV and Clinical Databases
- Time-consuming
- Manual work
![Page 8: Electronic Transfer of Serious Adverse Events to Global Pharmacovigilance PhUSE, Berlin, October 2010 Eva Bervar Bayer Vital GmbH, Leverkusen](https://reader036.vdocument.in/reader036/viewer/2022062718/56649e6a5503460f94b67a38/html5/thumbnails/8.jpg)
GCOData
Management
8
Requirements of the Electronic Process
• Study must be setup and conducted in EDC
• All relevant data must be available electronically (i.e. the information that is now documented on the paper complementary page)
• Transfer gateway required, which can be implemented either as
- Module / Interface of EDC system to PV System
or as
- SAS-based program interface between EDC & PV database
![Page 9: Electronic Transfer of Serious Adverse Events to Global Pharmacovigilance PhUSE, Berlin, October 2010 Eva Bervar Bayer Vital GmbH, Leverkusen](https://reader036.vdocument.in/reader036/viewer/2022062718/56649e6a5503460f94b67a38/html5/thumbnails/9.jpg)
GCOData
Management
9
Implementation in EDC
• Investigator must indicate that the SAE should be sent to GPV by selecting a check-box in EDC
• Last transfer date stored, if tick box is checked
• Identifier to send the data to PV Investigator decision
![Page 10: Electronic Transfer of Serious Adverse Events to Global Pharmacovigilance PhUSE, Berlin, October 2010 Eva Bervar Bayer Vital GmbH, Leverkusen](https://reader036.vdocument.in/reader036/viewer/2022062718/56649e6a5503460f94b67a38/html5/thumbnails/10.jpg)
GCOData
Management
10
Implementation of SAS-Based Solution
• E2B (E2B Plus = enhanced E2B)
- XML based Format
- Standardized exchange format
- Data exchange format between Pharmacovigilance and Regulatory Authorities
• SAS macro
- Executed on daily basis
- XML files sent to exchange directory and imported into PV system
- Investigator gets pdf version of SAE report per email for the site file
- Copy of mail sent to monitor
![Page 11: Electronic Transfer of Serious Adverse Events to Global Pharmacovigilance PhUSE, Berlin, October 2010 Eva Bervar Bayer Vital GmbH, Leverkusen](https://reader036.vdocument.in/reader036/viewer/2022062718/56649e6a5503460f94b67a38/html5/thumbnails/11.jpg)
GCOData
Management
11
Conclusions for Automated Process
Cons
• Still need extra reconciliation to show discrepancies between GDM and PV items
Pros
• Investigator only needs to document SAE once
• Reduction of discrepancies to a minimum
• Less time-consuming for investigator, DM and PV
• SAE reaches PV more quickly (although depends frequency DB replication)
![Page 12: Electronic Transfer of Serious Adverse Events to Global Pharmacovigilance PhUSE, Berlin, October 2010 Eva Bervar Bayer Vital GmbH, Leverkusen](https://reader036.vdocument.in/reader036/viewer/2022062718/56649e6a5503460f94b67a38/html5/thumbnails/12.jpg)
GCOData
Management
12
Thank you for your attention!
![Page 13: Electronic Transfer of Serious Adverse Events to Global Pharmacovigilance PhUSE, Berlin, October 2010 Eva Bervar Bayer Vital GmbH, Leverkusen](https://reader036.vdocument.in/reader036/viewer/2022062718/56649e6a5503460f94b67a38/html5/thumbnails/13.jpg)